

Please add the following new claims.

19. (New) A method of treatment of pain associated with non-constipated female IBS which comprises administering an effective amount of a 5-HT₃ receptor antagonist or a pharmaceutically acceptable derivative thereof.

20. (New) A method of treatment according to claim 19, wherein the 5-HT₃ receptor antagonist is alosetron or a pharmaceutically acceptable derivative thereof.

21. (New) A method of treatment according to claim 20, wherein alosetron is in the form of its hydrochloride.

22. (New) A method of improving stool consistency in a patient afflicted with non-constipated female IBS which comprises administering an effective amount of a 5-HT₃ receptor antagonist or a pharmaceutically acceptable derivative thereof.

23. (New) A method of treatment according to claim 22, wherein the 5-HT₃ receptor antagonist is alosetron or a pharmaceutically acceptable derivative thereof.

24. (New) A method of treatment according to claim 23, wherein alosetron is in the form of its hydrochloride.

25. (New) A method of decreasing urgency in a subject afflicted with non-constipated female IBS which comprises administering an effective amount of a 5-HT₃ receptor antagonist or a pharmaceutically acceptable derivative thereof.

26. (New) A method of treatment according to claim 25, wherein the 5-HT₃ receptor antagonist is alosetron or a pharmaceutically acceptable derivative thereof.